Danaher Corp (DHR) bonds
Close on Nov 16, 2026Market cap $161.75BP/E 37.6Yield –
Debt
Borrowings on the balance sheet, Sep 25, 2026
Total debt by fiscal year
Long-term plus current debt, USD
When the debt comes due
Principal repayments of long-term debt by fiscal year, as scheduled at Dec 31, 2025
From the debt maturity table in the annual report (filing). “Later” is everything due after year five.
Notes and loans outstanding
As tagged in Danaher's 10-Q for the period ended Sep 25, 2026
Coupon by maturity
Each circle is a note, sized by the amount issued. The line is what the US Treasury pays today for the same time to maturity.
| Issue | Coupon | Matures | Amount issued | Carrying value |
|---|---|---|---|---|
| 0.2% senior unsecured notes due 2026 | 0.20% | 2026 | €1.30B | €1.47B |
| 0.2% senior unsecured notes due 3/18/2026 (1.3 billion) (the 2026 Biopharma Euronotes) | 0.20% | 2026 | €1.30B | €0 |
| 2.1% senior notes due 2026 | 2.10% | 2026 | €800.00M | €940.00M |
| 2.100% Senior Notes due 2026 | 2.10% | 2026 | €800.00M | €912.00M |
| 2.100% Senior Notes due 2026 | 2.10% | 2026 | €800.00M | €912.00M |
| 0.3% senior unsecured notes due 2027 | 0.30% | 2027 | ¥30.80B | ¥196.00M |
| 0.3% senior unsecured notes due 5/11/2027 (30.8 billion) (the 2027 Yen Notes) | 0.30% | 2027 | ¥30.80B | ¥196.00M |
| 1.2% senior unsecured notes due 2027 | 1.20% | 2027 | €600.00M | €704.00M |
| 1.2% senior unsecured notes due 6/30/2027 (600 million) (the 2027 Euronotes) | 1.20% | 2027 | €600.00M | €683.00M |
| 0.45% senior unsecured notes due 2028 | 0.45% | 2028 | €1.30B | €1.47B |
| 0.45% senior unsecured notes due 3/18/2028 (1.3 billion) (the 2028 Biopharma Euronotes) | 0.45% | 2028 | €1.30B | €1.42B |
| 1.125% senior unsecured bonds due 12/08/2028 (CHF 210 million) (the 2028 CHF Bonds) | 1.12% | 2028 | CHF 210.00M | CHF 255.00M |
| 1.125% senior unsecured bonds due 2028 | 1.12% | 2028 | CHF 210.00M | CHF 267.00M |
| Floating rate senior unsecured notes due 4/29/2028 (500 million) (the 2028 Floating Rate Notes) | Floating | 2028 | €500.00M | €568.00M |
| 2.6% senior unsecured notes due 11/15/2029 ($800 million) (the 2029 Biopharma Notes) | 2.60% | 2029 | $800.00M | $798.00M |
| 3.250% senior unsecured notes due 4/29/2030 (750 million) (the 2030 Euronotes II) | 3.25% | Apr 30, 2030 | €750.00M | €850.00M |
| 2.5% senior notes due 2030 | 2.50% | 2030 | €800.00M | €940.00M |
| 2.500% Senior Notes due 2030 | 2.50% | 2030 | €800.00M | €912.00M |
| 1.65% senior unsecured bonds due 6/3/2031 (CHF 120 million) (the 2031 CHF Bonds) | 1.65% | Jun 30, 2031 | CHF 120.00M | CHF 143.00M |
| 0.750% Senior Notes due 2031 | 0.75% | Sep 30, 2031 | €1.80B | €1.99B |
| 0.75% senior notes due 2031 | 0.75% | 2031 | €1.80B | €2.01B |
| 0.75% senior unsecured notes due 2031 | 0.75% | 2031 | €1.80B | €2.05B |
| 0.65% senior unsecured notes due 2032 | 0.65% | 2032 | ¥53.20B | ¥339.00M |
| 0.65% senior unsecured notes due 5/11/2032 (53.2 billion) (the 2032 Yen Notes) | 0.65% | 2032 | ¥53.20B | ¥338.00M |
| 2033 CHF Notes II | 1.88% | Jun 30, 2033 | CHF 137.00M | CHF 165.00M |
| 1.265% senior unsecured bonds due 10/10/2033 (CHF 325 million) (the 2033 CHF Bonds) | 1.26% | Oct 31, 2033 | CHF 325.00M | CHF 390.00M |
| 2034 Euronotes | 3.62% | Apr 30, 2034 | €750.00M | €849.00M |
| 2.10% senior unsecured bonds due 6/3/2036 (CHF 221 million) (the 2036 CHF Bonds) | 2.10% | Jun 30, 2036 | CHF 221.00M | CHF 265.00M |
| 1.6249% senior unsecured bonds due 10/9/2037 (CHF 225 million) (the 2037 CHF Bonds) | 1.62% | Oct 31, 2037 | CHF 225.00M | CHF 270.00M |
| 4.000% senior unsecured notes due 4/29/2038 (1.0 billion) the (2038 Euronotes) | 4.00% | Apr 30, 2038 | €1.00B | €1.13B |
| 2038 CHF Notes | 2.25% | Jun 30, 2038 | CHF 373.00M | CHF 447.00M |
| 1.35% senior unsecured notes due 2039 | 1.35% | 2039 | €1.30B | €1.46B |
| 1.350% Senior Notes due 2039 | 1.35% | 2039 | €1.30B | €1.41B |
| 3.25% senior unsecured notes due 11/15/2039 ($900 million) (the 2039 Biopharma Notes) | 3.25% | 2039 | $900.00M | $893.00M |
| 2.38% senior unsecured bonds due 6/3/2041 (CHF 648 million) (the 2041 CHF Bonds) | 2.38% | Jun 30, 2041 | CHF 648.00M | CHF 777.00M |
| 4.375% senior unsecured notes due 2045 | 4.37% | 2045 | $500.00M | $500.00M |
| 4.375% senior unsecured notes due 9/15/2045 ($500 million) (the 2045 U.S. Notes) | 4.37% | 2045 | $500.00M | $500.00M |
| 2.51% senior unsecured bonds due 6/3/2046 (CHF 502 million) (the 2046 CHF Bonds) | 2.51% | Jun 30, 2046 | CHF 502.00M | CHF 601.00M |
| 1.800% Senior Notes due 2049 | 1.80% | Sep 30, 2049 | €750.00M | €846.00M |
| 1.8% senior notes due 2049 | 1.80% | 2049 | €750.00M | €857.00M |
| 1.8% senior unsecured notes due 2049 | 1.80% | 2049 | €750.00M | €873.00M |
| 3.4% senior unsecured notes due 11/15/2049 ($900 million) (the 2049 Biopharma Notes) | 3.40% | 2049 | $900.00M | $891.00M |
| 2.6% senior unsecured notes due 10/01/2050 ($1.0 billion) (the 2050 U.S. Notes) | 2.60% | 2050 | $1.00B | $983.00M |
| 2.8% senior unsecured notes due 12/10/2051 ($1.0 billion) (the 2051 U.S. Notes) | 2.80% | 2051 | $1.00B | $986.00M |
| 2056 CHF Notes | 2.50% | Jun 30, 2056 | CHF 382.00M | CHF 458.00M |
| 0.4773% 2027 CHF Bonds | 0.48% | – | CHF 250.00M | CHF 312.00M |
| 0.4773% senior unsecured bonds due 4/9/2027 (CHF 250 million) (the 2027 CHF Bonds)(f) | 0.48% | – | CHF 250.00M | CHF 301.00M |
| 0.8875% 2029 CHF Bonds | 0.89% | – | CHF 325.00M | CHF 405.00M |
| 0.8875% senior unsecured bonds due 10/10/2029 (CHF 325 million) (the 2029 CHF Bonds) | 0.89% | – | CHF 325.00M | CHF 391.00M |
| 1.265% 2033 CHF Bonds | 1.26% | – | CHF 325.00M | CHF 405.00M |
| 1.6249% 2037 CHF Bonds | 1.62% | – | CHF 225.00M | CHF 280.00M |
| 1.94% 2045 CHF Bonds | 1.94% | – | CHF 125.00M | CHF 155.00M |
| 1.94% senior unsecured notes due 10/10/2045 (CHF 125 million) (the 2045 CHF Notes) | 1.94% | – | CHF 125.00M | CHF 150.00M |
| Euro-Denominated Commercial Paper, 2026 Biopharma Euro Notes and 2026 Euro Notes | – | – | – | $3.50B |
| Euro-denominated commercial paper | – | – | – | €4.10B |
| Euro-denominated commercial paper | – | – | – | $4.70B |
| Other | – | – | – | $2.00M |
| Total Masimo Financing CHF Notes | – | – | CHF 2.38B | – |
| Total Masimo Financing Euronotes | – | – | €3.00B | – |
| Total Veralto debt | – | – | $2.60B | – |
| U.S. dollar-denominated commercial paper | – | – | – | $0 |
Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-Q.
Credit facilities
Revolving credit lines and other committed borrowing capacity
| Facility | Size | Drawn |
|---|---|---|
| 364-Day Facility | $5.00B | $0 |
| Multi-year Credit Facility | $5.00B | $0 |
| Multiyear Credit Facility, Superseded | $5.00B | – |
See a number that looks wrong?